Chief Business & Strategy Officer · Adaptimmune Therapeutics PLC (ADAP)

Helen Tayton-Martin

FY2023 is the first fiscal year CompBrief holds for Helen Tayton-Martin as a named executive officer of Adaptimmune Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$1,183,352

Salary $449,004Stock awards $0

3rd of 6 named executive officers at Adaptimmune Therapeutics by FY2023 total.

6 named officers on file for Adaptimmune Therapeutics, FY2023

Helen Tayton-Martin’s pay file — $29

  • 1 fiscal year of pay, line by line
  • ADAP’s disclosed peer group of 28 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Adaptimmune Therapeutics’s whole pay program stands against its peers

  • Adaptimmune Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ADAP→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 11, 2024 (DEF 14A).

Free

Get Helen Tayton-Martin’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Helen Tayton-Martin compensation by year

Adaptimmune Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Adaptimmune Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$449,004
Bonus$0
Stock awards$0
Option awards$505,950
Non-equity incentive$191,949
Pension and deferred compensation$0
All other$36,451
Total$1,183,352

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Adaptimmune Therapeutics PLC DEF 14A filed April 11, 2024, accession 0001104659-24-046093, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Adaptimmune Therapeutics PLC filed document, accession 0001104659-24-046093. Every figure is read from that document and cited to the page and table it appears in. Filed April 11, 2024.

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
Option121,356—$0.00
Option294,346—$0.97
Option197,064—$0.00
Option235,692—$0.00
Option732,894—$0.56
Option1,407,072—$0.33
Option26,203—$0.73
Option70,224—$0.00
Option314,256—$0.00

Per the Outstanding Equity Awards at Fiscal Year-End table in Adaptimmune Therapeutics PLC's FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Adaptimmune Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Adrian RawcliffeChief Executive Officer$2,774,041
William BertrandChief Operating Officer$1,215,100
Helen Tayton-Martin · this pageChief Business & Strategy Officer$1,183,352
Elliot NorryChief Medical Officer$1,180,968
Gavin WoodChief Financial Officer$1,171,239
Cintia PiccinaChief Commercial Officer$992,342

The full Adaptimmune Therapeutics compensation record

free company brief

This page is one person within Adaptimmune Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Adaptimmune Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Adaptimmune Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Helen Tayton-Martin's compensation dossier · One-time report. No refunds.